Of note, and only following combination treatment, Meso64-TR3 selectively eliminated the MUC16-positive cells from a mixed population of HPAC pancreatic cancer cells (Supplementary Figure S2A and S2B). This evidence concerns the gene MUC16 and pancreatic neoplasm.